

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Cost Comparison Appraisal

Atogepant for preventing migraine [ID5090]

Final Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • AbbVie (atogepant) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action on Pain • Brain and Spine Foundation • Brain Charity • Migraine Trust • National Migraine Centre • Neurological Alliance • OUCH UK • Pain Concern • Pain UK • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> • Association of British Neurologists • British Association for the Study of Headache • British Geriatrics Society • British Neuropathological Society • British Pain Society • Institute of Neurology • National Neuroscience Advisory Group • Neuromodulation Society of UK and Ireland • Physiotherapy Pain Association • Primary Care and Community Neurology Society • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • Neurological Alliance of Scotland • NHS Confederation • Scottish Medicines Consortium • Wales Neurological Alliance • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • AbbVie (botulinum toxin type A) • Eli Lilly (galcanezumab) • Lundbeck (eptinezumab) • Novartis (erenumab) • Pfizer (rimegepant) • Teva UK (fremanezumab) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Brain Research UK • Cochrane Pain, Palliative Care and Supportive Care Group • Cochrane UK • Genomics England • MRC Clinical Trials Unit

Stakeholder list for the evaluation of atogepant for preventing migraine ID5090

Issue date: January 2023

© National Institute for Health and Care Excellence 2023. All rights reserved.

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England 	<ul style="list-style-type: none"> • National Hospital for Neurology and Neurosurgery • National Institute for Health Research • Pain Relief Foundation <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.

groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.